Myriad Genetics, Inc. (MYGN)
3.805
+0.38
(+11.26%)
USD |
NASDAQ |
Sep 14, 16:00
3.74
-0.06
(-1.71%)
After-Hours: 18:25
Myriad Genetics Enterprise Value : 422.25M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 422.25M |
| September 10, 2026 | 416.52M |
| September 09, 2026 | 400.26M |
| September 08, 2026 | 399.31M |
| September 04, 2026 | 400.26M |
| September 03, 2026 | 404.09M |
| September 02, 2026 | 404.09M |
| September 01, 2026 | 399.31M |
| August 31, 2026 | 403.13M |
| August 28, 2026 | 397.40M |
| August 27, 2026 | 399.31M |
| August 26, 2026 | 393.57M |
| August 25, 2026 | 400.26M |
| August 24, 2026 | 386.88M |
| August 21, 2026 | 401.22M |
| August 20, 2026 | 403.13M |
| August 19, 2026 | 400.26M |
| August 18, 2026 | 369.67M |
| August 17, 2026 | 386.88M |
| August 14, 2026 | 384.97M |
| August 13, 2026 | 398.35M |
| August 12, 2026 | 404.09M |
| August 11, 2026 | 403.13M |
| August 10, 2026 | 406.00M |
| August 07, 2026 | 406.96M |
| Date | Value |
|---|---|
| August 06, 2026 | 399.31M |
| August 05, 2026 | 396.44M |
| August 04, 2026 | 398.35M |
| August 03, 2026 | 384.01M |
| July 31, 2026 | 368.72M |
| July 30, 2026 | 608.67M |
| July 29, 2026 | 577.12M |
| July 28, 2026 | 603.89M |
| July 27, 2026 | 616.32M |
| July 24, 2026 | 631.62M |
| July 23, 2026 | 640.22M |
| July 22, 2026 | 636.40M |
| July 21, 2026 | 660.30M |
| July 20, 2026 | 661.25M |
| July 17, 2026 | 686.11M |
| July 16, 2026 | 687.06M |
| July 15, 2026 | 698.54M |
| July 14, 2026 | 672.72M |
| July 13, 2026 | 655.52M |
| July 10, 2026 | 652.65M |
| July 09, 2026 | 678.46M |
| July 08, 2026 | 656.47M |
| July 07, 2026 | 655.52M |
| July 06, 2026 | 671.77M |
| July 02, 2026 | 667.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Natera, Inc. | 46.39B |
| Sera Prognostics, Inc. | 36.62M |
| BioRestorative Therapies, Inc. | -0.1562M |
| CareDx, Inc. | 2.233B |
| Exagen, Inc. | 173.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.20M |
| Revenue (Quarterly) | 190.70M |
| Total Expenses (Quarterly) | 233.90M |
| EPS Diluted (Quarterly) | -0.4557 |
| Gross Profit Margin (Quarterly) | 62.51% |
| Profit Margin (Quarterly) | -22.65% |
| Earnings Yield | -31.50% |
| Normalized Earnings Yield | -29.91 |